Cholesterol levels of Japanese dyslipidaemic patients with various comorbidities: BioBank Japan
-
- Yokomichi Hiroshi
- Department of Health Sciences, University of Yamanashi
-
- Nagai Akiko
- Department of Public Policy, Institute of Medical Science, The University of Tokyo
-
- Noda Hokuto
- Department of Health Sciences, University of Yamanashi
-
- Hirata Makoto
- Laboratory of Genome Technology, Institute of Medical Science, The University of Tokyo
-
- Kiyohara Yutaka
- Hisayama Research Institute for Lifestyle Diseases
-
- Kamatani Yoichiro
- Laboratory for Statistical Analysis, RIKEN Center for Integrative Medical Sciences
-
- Matsuda Koichi
- Laboratory of Molecular Medicine, Institute of Medical Science, The University of Tokyo
-
- Tamakoshi Akiko
- Department of Public Health, Hokkaido University Graduate School of Medicine
-
- Muto Kaori
- Department of Public Policy, Institute of Medical Science, The University of Tokyo
-
- Ninomiya Toshiharu
- Department of Epidemiology and Public Health, Graduate School of Medical Sciences, Kyushu University
-
- Nakamura Yusuke
- Laboratory of Molecular Medicine, Institute of Medical Science, The University of Tokyo
-
- Kubo Michiaki
- RIKEN Center for Integrative Medical Sciences
-
- Yamagata Zentaro
- Department of Health Sciences, University of Yamanashi
書誌事項
- 公開日
- 2017
- 資源種別
- journal article
- DOI
-
- 10.1016/j.je.2016.12.014
- 公開者
- 日本疫学会
この論文をさがす
説明
<p>Background: Controlling serum cholesterol is critical to prevent cardiovascular disease in patients with dyslipidaemia. Guidelines emphasise the need to select treatment for dyslipidaemia based on specific patient profiles; however, there is little information about the serum cholesterol levels of patients in each profile in Japan. Therefore, we aimed to describe the serum cholesterol levels and prevalence of uncontrolled cases in Japanese patients with dyslipidaemia.</p><p>Methods: We included data for patients with dyslipidaemia between 2003 and 2007 from the BioBank Japan Project (66 hospitals). Then, we reported their serum cholesterol levels by age, body mass index, glycaemic control (glycated haemoglobin A1c), blood pressure, smoking, drinking, comorbidity and medication profiles.</p><p>Results: We included 22,189 male and 21,545 female patients. The mean serum low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglyceride (TG) and non-HDL-C levels in males were 117.4 mg/dL, 51.0 mg/dL, 187.6 mg/dL and 153.6 mg/dL, respectively; the corresponding levels in females were 129.5 mg/dL, 60.5 mg/dL, 144.9 mg/dL and 157.9 mg/dL, respectively. In both males and females, the LDL-C levels were the highest in the following profiles: age 19–44 years, body mass index 18.5–22 kg/m2, glycated haemoglobin A1c <6.0%, never smoker, chronic respiratory disease as a comorbidity and no medication use.</p><p>Conclusions: These data provide details of serum cholesterol levels by risk-factor profile in patients with dyslipidaemia and could add evidence of treatment decisions.</p>
収録刊行物
-
- Ｊｏｕｒｎａｌ ｏｆ Ｅｐｉｄｅｍｉｏｌｏｇｙ
-
Ｊｏｕｒｎａｌ ｏｆ Ｅｐｉｄｅｍｉｏｌｏｇｙ 27 (Supplement_III), S77-S83, 2017
日本疫学会
